Stockscreener 앱 받기
11.05
3.58%
-0.41
Mink Therapeutics Inc 주식(INKT)의 최신 뉴스
Mink Therapeutics (INKT) Proxy filing Summary - Quartr
Mink Therapeutics (INKT) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary - Quartr
Mink Therapeutics (INKT) Q1 2025 earnings summary - Quartr
Cost of goods sold of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView
Understanding Momentum Shifts in (INKT) - Stock Traders Daily
MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Value Benchmark Index - marketscreener.com
MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Growth Benchmark Index - marketscreener.com
MiNK Therapeutics, Inc.(NasdaqCM: INKT) added to Russell 3000E Growth Benchmark - marketscreener.com
MiNK Therapeutics, Inc.(NasdaqCM: INKT) added to Russell Microcap Index - marketscreener.com
MiNK Therapeutics, Inc.(NasdaqCM: INKT) added to Russell 3000E Value Benchmark - marketscreener.com
MiNK Therapeutics Advances Phase 2 Trial of agenT-797 in Severe Pneumonia: What Investors Should Watch - TipRanks
Enterprise value to EBITDA forward of MiNK Therapeutics, Inc. – NASDAQ:INKT - TradingView
MiNK Therapeutics, Inc. Actuals & Estimates (NASDAQ:INKT) - TradingView
Price to earnings forward of MiNK Therapeutics, Inc. – NASDAQ:INKT - TradingView
Price to sales forward of MiNK Therapeutics, Inc. – NASDAQ:INKT - TradingView
INKT Forecast — Price Target — Prediction for 2027 - TradingView
MiNK Therapeutics Stockholders Back Directors, Ratify Auditor - The Globe and Mail
Total liabilities & shareholders' equities of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView
Form 8K Mink Therapeutics Inc For: 23 June By Investing.com - Investing.com South Africa
MiNK Therapeutics (INKT) investors reelect board members and ratify KPMG at 2026 meeting - Stock Titan
MiNK Therapeutics (INKT) Edges Higher, Approaching Key Resistance at $12.88Liquidity Sweep - dars.gov.et
Avoiding Lag: Real-Time Signals in (INKT) Movement - Stock Traders Daily
Inventory turnover of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView
Diluted net income available to common stockholders of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView
After tax other income/expense of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView
Book value per share of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView
MiNK Therapeutics, Inc. Cash Flow – DUS:6Q40 - TradingView
Debt to equity ratio of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView
Mink Therapeutics Inc (INKT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mink Therapeutics Inc (INKT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mink Therapeutics Inc (INKT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Mink Therapeutics Inc (INKT) Institutional Confidence - TradingKey
Mink Therapeutics Inc (INKT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mink Therapeutics (INKT) Q1 2026 earnings summary - Quartr
Mink Therapeutics (INKT) AGM 2026 Summary - Quartr
INKT: Directors and auditor elected, immune restoration strategy advanced, and global trials expanded - TradingView
Mink Therapeutics Inc (INKT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mink Therapeutics Inc (INKT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mink Therapeutics Inc (INKT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mink Therapeutics Inc (INKT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Number of shareholders of MiNK Therapeutics, Inc. – NASDAQ:INKT - TradingView
Number of shareholders of MiNK Therapeutics, Inc. – FWB:6Q40 - TradingView
INKT Technical Analysis & Stock Price Forecast - Intellectia AI
MiNK Therapeutics (INKT) Rallies 1.19% as Support Holds Firm Near $11.72IV Contraction - newsline.com
INKT Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Investor SentimentProfit Warning Alert - newsline.com
Discipline and Rules-Based Execution in INKT Response - Stock Traders Daily
Number of shareholders of MiNK Therapeutics, Inc. – LS:A40ZAV - TradingView
INKT Q1 2026 Earnings: EPS Beat on Narrower Loss, But Stock Drops 5%Quarterly Earnings Report - newsline.com
MiNK Therapeutics (INKT) Pulls Back Sharply: Support Test LoomsStrangle Setup - newsline.com
Mink Therapeutics director Barbara Ryan sells $19,141 in stock By Investing.com - Investing.com India
Insider Sell: Barbara Ryan Sells 1,500 Shares of MiNK Therapeuti - GuruFocus
MiNK Therapeutics Q1 earnings call highlights - MSN
Mink Therapeutics director Barbara Ryan sells $19,141 in stock - Investing.com
Director at MiNK Therapeutics (NASDAQ: INKT) sells 1,500 shares - Stock Titan
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting - The Manila Times
How to join MiNK Therapeutics’ June 17 virtual shareholder meeting - Stock Titan
2.64%
자본화:
|
볼륨(24시간):